JWH-018
JWH-018 is a synthetic cannabinoid of the naphthoylindole class.1 It gained widespread recognition from 2006 onward as the primary active ingredient in "Spice" brand herbal smoking blends, which were marketed as potpourri and labeled "not for human consumption." The Spice brand became so dominant that the name was eventually adopted as a generic term for all synthetic cannabinoids. JWH-018 produces cannabis-like effects when smoked but carries the heightened risks characteristic of synthetic cannabinoid compounds.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Dosing information for smoked JWH-018 derives primarily from oral administration reports and animal research rather than controlled human inhalation studies. Threshold effects have been observed at sub-milligram quantities, though an exact threshold dose has not been determined in published literature. As with other synthetic cannabinoids, considerable variation in potency has been documented across different batches and synthesis methods.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
Cognitive
Visual
Auditory
Pharmacology
Pharmacodynamics
JWH-018 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2.citation needed It displays binding affinities of 9.00 ± 5.00 nM at CB1 and 2.94 ± 2.65 nM at CB2, with its CB1 affinity reported as approximately five times greater than that of THC. Unlike THC, which acts as a partial agonist at CB1, JWH-018's full agonist activity produces more complete receptor activation.
Pharmacokinetics
JWH-018 undergoes extensive metabolism primarily through hydroxylation and N-dealkylation.citation needed In humans, metabolism occurs mainly on the indole ring and pentyl side chain, with the resulting hydroxylated metabolites undergoing extensive glucuronide conjugation.2 The parent compound and its N-dealkylated metabolite are detected only in small quantities in urine, while hydroxylated N-dealkylated metabolites constitute the primary urinary signal.citation needed When inhaled, the median elimination half-life is approximately 1.69 hours.
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Cannabinoids (including THC and other synthetic cannabinoid receptor agonists)
Harm Potential
Addiction & Dependence
Psychological
ModerateAt least one case of JWH-018 dependence has been reported following daily use over eight months.citation needed As a full CB1 agonist with indirect dopaminergic activity, JWH-018 may have greater reinforcing potential than cannabis, though individual susceptibility varies.
Physical
LowWithdrawal symptoms have been reported following prolonged daily use and were described as more severe than those experienced from cannabis dependence.citation needed
Psychosis Risk
May cause intense anxiety and agitation. Psychotic relapses and anxiety symptoms have been reported in patients with pre-existing mental illness following inhalation.3 Due to concerns about psychosis induction in vulnerable individuals, it is recommended that people with risk factors for psychotic disorders, such as a past or family history of psychosis, not use synthetic cannabinoids.citation needed
Seizure Risk
Seizures and convulsions have been reported in rare cases, though causation has not been definitively established.citation needed
History & Culture
Legality
By Country
References
Source Pages
Citations
- Liana Fattore, & Walter Fratta. (2011). Beyond THC: The New Generation of Cannabinoid Designer Drugs. https://doi.org/10.3389/fnbeh.2011.000601
- Tim Sobolevsky, Ilya Prasolov, & Grigory Rodchenkov. (July 2010). Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Science International, 200(1–3), 141–7. https://doi.org/10.1016/j.forsciint.2010.04.0031
- Susanna Every-Palmer. (September 2011). Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug and Alcohol Dependence, 117(2–3), 152–157. https://doi.org/10.1016/j.drugalcdep.2011.01.0121
- Huffman, John W.. (2005). Synthesis of Cannabinoid Receptor Ligands — NIH NIDA grant K05-DA015340. National Institute on Drug Abuse / Grantome. https://grantome.com/grant/NIH/K05-DA015340-031
- The Unlikely Clemson Chemist Behind Synthetic Marijuana. (n.d.). https://www.wfae.org/local-news/2011-01-25/the-unlikely-clemson-chemist-behind-synthetic-marijuana1
- Suchtgiftverordnung. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Anlage=4&Artikel=&Gesetzesnummer=10011053&Paragraf=&ShowPrintPreview=True&Uebergangsrecht=1
- Controlled Drugs and Substances Act. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html1
- Bekendtgørelse om euforiserende stoffer (BEK nr 405 af 26/03/2026), liste B. retsinformation.dk (n.d.). https://www.retsinformation.dk/api/pdf/2559321
- Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista (543/2008). finlex.fi (n.d.). https://www.finlex.fi/fi/lainsaadanto/2008/5431
- Betäubungsmittelgesetz. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html1
Further Reading
Brents et al. (2011) - Phase I Metabolites Activity
CYP2C9 polymorphism metabolism
Freeman et al. (2013) - Stroke Association
Grigoryev et al. (2022) - Psychotomimetic Effects Study
Human Inhalation Pharmacokinetics (2–3 mg)
Human inhalation PK (2–3 mg)
JWH-018 Phase 1 Pilot Study
Koller et al. (2022) - Cannabinoid-Induced Seizures
Phase-1 pilot, 2 & 3 mg inhaled
Psychotomimetic 5.5 mg study
Rat tolerance & CB1 desensitisation
Rat Tolerance and CB1 Desensitization
Schneir et al. (2011) - Synthetic Cannabinoid Intoxication
Severe toxicity with seizures
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
26 August 2026
Lyrea · Edited in History & Culture › Sections 2 › Content
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the JWH-018 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.